

21 September 2018

NSX Announcement

Extension of Payment Date for Medicine Plus Transaction

On 20 June 2018, Beroni Group (NSX:BTG) (“Beroni” or the “Company”) advises that it has entered into a binding agreement to acquire 100% of Medicine Plus Co., Ltd, (“MP”), a pharmaceutical company based in Osaka, Japan (“Transaction”). Beroni will acquire MP for JPY1.178 billion (A\$14.37 million¹) via a combination of cash and shares (“Consideration”). The Transaction is subject to regulatory approvals for the change in ownership of licenses and permits to sell medicine, and approvals from other contractual parties.

The Transaction requires Beroni to pay the Consideration by 20 September 2018. The Company is pleased to advise that it has entered into a variation deed with MP to extend the payment date of the Consideration to 20 November 2018. Total Consideration is increased by 10% to approximately \$15.8 million. Beroni will provide an update on the progress of funding to conclude the Transaction in due course.

Note 1: Exchange rate of A\$1 = JPY 82 used

For further information please contact:

Mr Jacky Zhang
Executive Chairman
Tel: +86 1851 6931 911
E: 1710426553@qq.com

Mr Peter Wong
Non-Executive Director
Tel: +61 423 727 580
E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX:BTG) (FSE:6B9)

Beroni Group is a Chinese biotechnological company which is dual listed on the National Stock Exchange (Australia) and Frankfurt Stock Exchange. Its business mainly focuses on biotechnology, life sciences, environmental science and governance, precision medicine, regenerative medicine, and stem cell anti-cancer and anti-aging projects. Beroni Group’s overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries.